| Pamela Ruth Ator, MD | |
|
1010 Sheridan St, Port Townsend, WA 98368-2901 | |
| (360) 385-3500 | |
| Not Available |
| Full Name | Pamela Ruth Ator |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 31 Years |
| Location | 1010 Sheridan St, Port Townsend, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780656488 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | MD18775 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jefferson Healthcare Home Health | Port townsend, WA | Home health agency |
| Jefferson Healthcare Home Health | Pt townsend, WA | Hospice |
| Jefferson Healthcare | Port townsend, WA | Hospital |
| Olympic Medical Center | Port angeles, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jefferson County Public Hospital District No 2 | 4789593708 | 105 |
News Archive
Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.
Researchers of Kaunas University of Technology, the Lithuanian University of Health Sciences and Italian high-tech company Gruppo Fos Lithuania are developing innovative technology for the personalized care of the patients who have experienced a stroke.
Cover your mouth when sneezing or coughing and wash your hands. Queensland University of Technology and The University of Queensland scientists have developed a new technique to study how some common disease-causing bacteria can spread up to 4m and remain alive in the air for up to 45 minutes.
Researchers at Cedars-Sinai Medical Center announced today the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a new, minimally-invasive option for those suffering with advanced widespread emphysema.
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
› Verified 1 days ago
| Entity Name | Jefferson County Public Hospital District No 2 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356492953 PECOS PAC ID: 4789593708 Enrollment ID: O20031111000542 |
News Archive
Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.
Researchers of Kaunas University of Technology, the Lithuanian University of Health Sciences and Italian high-tech company Gruppo Fos Lithuania are developing innovative technology for the personalized care of the patients who have experienced a stroke.
Cover your mouth when sneezing or coughing and wash your hands. Queensland University of Technology and The University of Queensland scientists have developed a new technique to study how some common disease-causing bacteria can spread up to 4m and remain alive in the air for up to 45 minutes.
Researchers at Cedars-Sinai Medical Center announced today the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a new, minimally-invasive option for those suffering with advanced widespread emphysema.
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pamela Ruth Ator, MD 834 Sheridan St, Port Townsend, WA 98368-2443 Ph: (360) 385-2200 | Pamela Ruth Ator, MD 1010 Sheridan St, Port Townsend, WA 98368-2901 Ph: (360) 385-3500 |
News Archive
Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.
Researchers of Kaunas University of Technology, the Lithuanian University of Health Sciences and Italian high-tech company Gruppo Fos Lithuania are developing innovative technology for the personalized care of the patients who have experienced a stroke.
Cover your mouth when sneezing or coughing and wash your hands. Queensland University of Technology and The University of Queensland scientists have developed a new technique to study how some common disease-causing bacteria can spread up to 4m and remain alive in the air for up to 45 minutes.
Researchers at Cedars-Sinai Medical Center announced today the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a new, minimally-invasive option for those suffering with advanced widespread emphysema.
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
› Verified 1 days ago
Karen D Forbes, M.D. Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 934 Sheridan St, Port Townsend, WA 98368 Phone: 360-385-3500 Fax: 360-385-5496 | |
Catherine Anne Parkman, M.D. Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 934 Sheridan St, Port Townsend, WA 98368 Phone: 360-385-5330 Fax: 360-385-0206 | |
Dr. Frank W. Torres, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 834 Sheridan St, Port Townsend, WA 98368 Phone: 360-344-1001 Fax: 360-412-6473 | |
Gary C Forbes, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 934 Sheridan St, Port Townsend, WA 98368 Phone: 360-385-5330 Fax: 360-385-0206 | |
Mary Sarah Ferguson, M.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 2881 Cape George Rd, Port Townsend, WA 98368 Phone: 510-882-6107 Fax: 925-307-5742 | |
Sandra Eilene Smith-poling, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 2112 Landes St, Port Townsend, WA 98368 Phone: 360-379-0841 Fax: 360-379-0841 | |
Dr. John E Sailer, M.D. Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 181 Saddle Drive, Port Townsend, WA 98368 Phone: 360-379-9010 |